Keyphrases
Papillomavirus Infections
100%
Cervical Cancer
100%
Human Papillomavirus Testing
80%
Castle
60%
High-risk Human Papillomavirus (HR-HPV)
60%
Human Papillomavirus Types
60%
Natural History
40%
Northern California
40%
Guanacaste
40%
Cervical Neoplasia
40%
Portland
40%
Risk Biomarkers
40%
Nigeria
40%
Kaiser Permanente
40%
HPV16
40%
Schiffman
40%
Human Papillomavirus DNA
40%
Longitudinal Data
20%
Cervix
20%
Screening Coverage
20%
Absolute Risk
20%
Clinic-based
20%
New Humanities
20%
Human Papillomavirus Prevalence
20%
Low-resource Countries
20%
Infection Rate
20%
Transformation Zone
20%
Longitudinal Analysis
20%
Database Management Systems
20%
Frozen Specimen
20%
Ectocervix
20%
Cooperation Agreements
20%
Molecular Screening
20%
Antagonism
20%
Risk of Progression
20%
Immune Control
20%
Precancer
20%
Tumor Suppressor Gene
20%
Neoplastic Progression
20%
HPV18
20%
High Prevalence
20%
U.S. National Library of Medicine
20%
Screening Accuracy
20%
Clinical Trials
20%
Screening Strategy
20%
Multiple Infections
20%
Anal Neoplasia
20%
Non-carcinogenic
20%
Cohort Analysis
20%
Screening Program
20%
Screening Test
20%
Viral Persistence
20%
Prospective Follow-up
20%
Inapparent
20%
Work Research
20%
Age-specific
20%
Disease Stage
20%
Oklahoma
20%
Molecular Events
20%
Older Women
20%
Prevalence Rate
20%
Albert Einstein
20%
Endocervix
20%
Visual Appearance
20%
Progressive Disease
20%
Rural China
20%
Rational Screening
20%
Final Testing
20%
School of Medicine
20%
Mississippi Delta
20%
Self-sampling
20%
Multimedia Databases
20%
Medicine and Dentistry
Cervical Cancer
100%
Papillomavirus Infection
100%
Wart Virus
100%
Cohort Analysis
30%
Infection
23%
Neoplasm
23%
Health Care Cost
15%
Medicine
15%
Precancerous Condition
15%
Cytotechnology
15%
Human Papillomavirus Type 16
15%
Prevalence
15%
Biological Marker
15%
Cervix
7%
Progressive Disease
7%
Cross Sectional Study
7%
Human Papillomavirus Type 18
7%
Screening Test
7%
Clinical Trial
7%
Tumor Suppressor Gene
7%
Mixed Infection
7%
Pharmacology, Toxicology and Pharmaceutical Science
Papillomavirus Infection
100%
Uterine Cervix Cancer
100%
Human Papillomavirus
100%
Infection
23%
Neoplasm
23%
Cohort Study
23%
Human Papillomavirus Type 16
15%
Biological Marker
15%
Precancer
15%
Prevalence
15%
Clinical Trial
7%
Human Papillomavirus Type 18
7%
Mixed Infection
7%
Tumor Suppressor Protein
7%
Diseases
7%
Cross-Sectional Study
7%